Jannet Kocerha

Prof. Jannet Kocerha

Georgia Southern University, Statesboro, Georgia, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
JHJohora Hanna
Johora Hanna
GHGazi S. Hossain
Gazi S. Hossain
JKJannet Kocerha
Jannet Kocerha
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of nonprotein-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.

13 June 2014 in Molecular Brain
Verified
Journal Article
Open access
PDF file
JKJannet Kocerha
Jannet Kocerha
YXYan Xu
Yan Xu
MPMelinda S Prucha
Melinda S Prucha
DZDongming Zhao
Dongming Zhao
ACAnthony W.S. Chan
Anthony W.S. Chan
Huntington’s Disease (HD) is a progressive neurodegenerative disorder with a single causal mutation in the Huntingtin (HTT) gene. MicroRNAs (miRNAs) have recently been implicated as epigenetic regulators of neurological disorders, however, their role in HD pathogenesis is not well defined. Here we study transgenic HD monkeys (HD monkeys) to examine miRNA dysregulation in a primate model of the disease.

31 March 2015 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JKJannet Kocerha
Jannet Kocerha
YDY Dwivedi
Y Dwivedi
KBK J Brennand
K J Brennand
The human genome project has revolutionized our understanding of the underlying mechanisms in psychiatric disease. It is now abundantly clear that neurobehavioral phenotypes are epigenetically controlled by noncoding RNAs (ncRNAs). The microRNA (miRNA) class of ncRNAs are ubiquitously expressed throughout the brain and govern all major neuronal pathways. The attractive therapeutic potential of miRNAs is underscored by their pleiotropic capacities, putatively targeting multiple pathways within a single neuron. Many psychiatric diseases stem from a multifactorial origin, thus conventional drug targeting of single proteins may not prove most effective. In this exciting post-genome sequencing era, many new epigenetic targets are emerging for therapeutic investigation. Here we review the reported roles of miRNAs, as well as other ncRNA classes, in the pathology of psychiatric disorders; there are both common and unique ncRNA mechanisms that influence the various diagnoses. Collectively, these potent epigenetic regulators may clarify the disrupted signaling networks in psychiatric phenotypes.

9 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
Grace BlountGrace Blount
Grace Blount
LCLayton Coursey
Layton Coursey
JKJannet Kocerha
Jannet Kocerha
The change from viewing noncoding RNA as “junk” in the genome to seeing it as a critical epigenetic regulator in almost every human condition or disease has forced a paradigm shift in biomedical and clinical research. Small and long noncoding RNA transcripts are now routinely evaluated as putative diagnostic or therapeutic agents. A prominent role for noncoding microRNAs in the central nervous system has uncovered promising new clinical candidates for dementia-related disorders, treatments for which currently remain elusive even as the percentage of diagnosed patients increases significantly. Cognitive decline is a core neurodegenerative process in Alzheimer’s Disease, Frontotemporal Dementia, Lewy body dementia, vascular dementia, Huntington’s Disease, Creutzfeldt–Jakob disease, and a significant portion of Parkinson’s Disease patients. This review will discuss the microRNA-associated networks which influence these pathologies, including inflammatory and viral-mediated pathways (such as the novel SARS-CoV-2 virus implicated in COVID-19), and their current status in clinical trials.

25 October 2016 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
WCWilliam T. Carrick
William T. Carrick
BBBrandi Burks
Brandi Burks
Murray J. CairnsMurray J. Cairns
Murray J. Cairns
JKJannet Kocerha
Jannet Kocerha
Dopaminergic neurotransmission mediates a majority of the vital central nervous system functions. Disruption of these synaptic events provokes a multitude of neurological pathologies, including Parkinson’s, schizophrenia, depression and addiction. Growing evidence supports a key role for noncoding RNA (ncRNA) regulation in the synapse. This review will discuss the role of both short and long ncRNAs in dopamine signaling, including bioinformatic examination of the pathways they target. Specifically, we focus on the contribution of ncRNAs to dopaminergic dysfunction in neurodegenerative as well as psychiatric disease.

9 July 2024 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
GBGrace S. Blount
Grace S. Blount
ASAustin Seymour
Austin Seymour
DWDylan Williams
Dylan Williams
DDDaylon Douglas
Daylon Douglas
JMJoshua Miller
Joshua Miller
KAKarelle Aiken
Karelle Aiken